
Liquidia Corporation LQDA
$ 54.39
-4.09%
Liquidia Corporation Interest Expense | LQDA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Liquidia Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 6.27 M | 2.34 M | 762 K | 858 K | 1.37 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.27 M | 762 K | 2.32 M |
Quarterly Interest Expense Liquidia Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 3 M | 2.6 M | 2.52 M | 1.96 M | 1.76 M | 1.43 M | 1.12 M | 698 K | 620 K | 542 K | 478 K | 204 K | 205 K | 203 K | 150 K | - | 191 K | 211 K | 255 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3 M | 150 K | 1.01 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
57 K | $ 3.11 | -8.94 % | $ 482 M | ||
|
Galapagos NV
GLPG
|
1.03 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
31 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
741 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-36 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
54 K | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
683 K | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
3.02 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
1.2 M | - | - | $ 24.2 M | ||
|
Myovant Sciences Ltd.
MYOV
|
14 M | - | -0.04 % | $ 2.62 B | ||
|
Idera Pharmaceuticals
IDRA
|
7 K | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
340 K | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
7.27 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
2.13 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-994 K | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
179 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
5.81 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-47 K | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
12.7 K | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-27.9 K | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
1.24 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
20.9 K | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
44.2 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
1.2 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
2.9 K | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-4.81 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
2.29 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
604 K | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-234 K | - | - | $ 127 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-357 K | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
-1 M | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
117 K | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | ||
|
Orgenesis
ORGS
|
-4.51 M | - | -33.86 % | $ 61.2 M |